KALA BIO, Inc.
KALANASDAQHealthcare● Active
$2.30
+$0.24(+11.56%)
Market Cap$50399526
P/E Ratio—
52W High$1030
52W Low$2.1
KALA BIO, Inc. (KALA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KALA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.14
Est. -$8.50 · +98.3%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
KALA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$6.00 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$8.50 | -$0.14 | +98.3% | — | — | — |
| ▲ Q2 FY2026 | Apr 15, 2026 | -$16.00 | $0.08 | +100.5% | — | — | — |
| ▼ Q4 FY2025 | Nov 19, 2025 | -$1.01 | -$1.07 | -5.9% | — | — | — |
| ▲ Q3 FY2025 | Aug 8, 2025 | -$1.82 | -$1.71 | +6.0% | — | — | — |
| ▲ Q2 FY2025 | May 14, 2025 | -$2.03 | -$1.41 | +30.5% | — | — | — |
| ▲ Q1 FY2025 | Mar 31, 2025 | -$2.28 | -$1.74 | +23.7% | $0.00B | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$2.43 | -$1.93 | +20.6% | — | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$6.00
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.14
EPS Est.
-$8.50
EPS Surpr.
+98.3%
Revenue
—
Q2 FY2026
Apr 15, 2026Beat
EPS Actual
$0.08
EPS Est.
-$16.00
EPS Surpr.
+100.5%
Revenue
—
Q4 FY2025
Nov 19, 2025Miss
EPS Actual
-$1.07
EPS Est.
-$1.01
EPS Surpr.
-5.9%
Revenue
—
Q3 FY2025
Aug 8, 2025Beat
EPS Actual
-$1.71
EPS Est.
-$1.82
EPS Surpr.
+6.0%
Revenue
—
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$1.41
EPS Est.
-$2.03
EPS Surpr.
+30.5%
Revenue
—
Q1 FY2025
Mar 31, 2025Beat
EPS Actual
-$1.74
EPS Est.
-$2.28
EPS Surpr.
+23.7%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$1.93
EPS Est.
-$2.43
EPS Surpr.
+20.6%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-5.50 | $-5.50 | $-5.50 | 1 |
| Q3 FY2026 | $-6.00 | $-6.00 | $-6.00 | 1 |
| Q2 FY2026 | $-6.00 | $-6.00 | $-6.00 | 1 |
| Q1 FY2026 | $-8.50 | $-8.50 | $-8.50 | 1 |
| Q4 FY2025 | $-16.00 | $-16.00 | $-16.00 | 1 |
| Q3 FY2025 | $-1.01 | $-1.01 | $-1.01 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +98.3% | $3.09 | $2.93 | -5.18% |
| ▲ Q2 FY2026 | Apr 15, 2026 | +100.5% | $11.29 | $9.94 | -11.96% |
| ▼ Q4 FY2025 | Nov 19, 2025 | -5.9% | $34.44 | $31.65 | -8.10% |
| ▲ Q3 FY2025 | Aug 8, 2025 | +6.0% | $358.00 | $369.00 | +3.07% |
| ▲ Q2 FY2025 | May 14, 2025 | +30.5% | $174.00 | $163.50 | -6.03% |
| ▲ Q1 FY2025 | Mar 31, 2025 | +23.7% | $302.50 | $286.50 | -5.29% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +20.6% | $370.00 | $354.50 | -4.19% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +28.3% | $297.50 | $309.50 | +4.03% |
Q2 FY2026-5.18%
Report Date
May 15, 2026
EPS Beat/Miss
+98.3%
Price Before
$3.09
Price After
$2.93
Q2 FY2026-11.96%
Report Date
Apr 15, 2026
EPS Beat/Miss
+100.5%
Price Before
$11.29
Price After
$9.94
Q4 FY2025-8.10%
Report Date
Nov 19, 2025
EPS Beat/Miss
-5.9%
Price Before
$34.44
Price After
$31.65
Q3 FY2025+3.07%
Report Date
Aug 8, 2025
EPS Beat/Miss
+6.0%
Price Before
$358.00
Price After
$369.00
Q2 FY2025-6.03%
Report Date
May 14, 2025
EPS Beat/Miss
+30.5%
Price Before
$174.00
Price After
$163.50
Q1 FY2025-5.29%
Report Date
Mar 31, 2025
EPS Beat/Miss
+23.7%
Price Before
$302.50
Price After
$286.50
Q4 FY2024-4.19%
Report Date
Nov 12, 2024
EPS Beat/Miss
+20.6%
Price Before
$370.00
Price After
$354.50
Q3 FY2024+4.03%
Report Date
Aug 6, 2024
EPS Beat/Miss
+28.3%
Price Before
$297.50
Price After
$309.50
Avg Beat Reaction-3.65%
Avg Miss Reaction-8.10%
Beat Rate7 / 8 quarters
Largest Move-11.96% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KALA ends December
KALA BIO, Inc. (KALA) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.14 — beating the analyst consensus of $-8.50 by +98.3%. KALA has beaten EPS estimates for 2 consecutive quarters. The next KALA earnings date is expected around September 1, 2026.
Each quarter, investors track KALA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KALA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KALA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KALA earnings · 5 questionsKALA BIO, Inc.'s next earnings report is expected around September 1, 2026. KALA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KALA historically reports after market close (AMC).
KALA earnings datewhen is KALA earningsKALA next earnings datewhen does KALA report earningsKALA earnings calendar
▸ Source: FMP · KALA BIO, Inc. SEC filings · US GAAP · KALA BIO, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026